Court rejects Celexa patent listing
FDA's "ministerial" role in declining to list certain patents in the "Orange Book" affirmed by a D.C. federal judge Aug. 13. Court rules FDA did not err in refusing Alphapharm's request to list a patent for Forest's antidepressant Celexa and accept its ANDA with a Paragraph IV certification. No patents for Celexa are listed; consequently, no ANDA filers will receive 180-day exclusivity for generic citalopram...
You may also be interested in...
In this new roundup feature focusing on the most notable developments in digital health, we pick the key news from the year so far.
US Regulatory Roundup, February 2021: QA/RA Predictions, FDA Warning Letter Stats, PMA Case Study, And More
Quality and regulatory predictions for 2021, a count of 2020 US FDA enforcement missives, a premarket approval case study for a novel prosthetic, and more topped our list of most-read Medtech Insight articles in February.
Locke Lord senior counsel Sharon Blinkoff shares perspective from her experience defending smaller cosmetics companies against US class action plaintiff demands and litigation.